Hester Biosciences cash flow

Latest FY26

Cash from operations: ₹64.1cr−0.6% on FY25
Capital spending: ₹17.8cr−13.4% on FY25
Free cash flow: ₹46.3cr+5.4% on FY25
Cash from financing: −₹48.8cr−₹51.7 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	18.9	16.8	17.2	9.4
	—	10.3	12.2	19.5	9.0
	—	−1.6	−2.0	−1.9	−2.2
	—	−1.8	0.0	0.0	0.0
	—	10.9	−0.8	−0.1	0.1
	—	6.2	4.4	−5.8	0.0
	—	−2.9	0.0	0.0	0.0
	—	0.0	0.0	0.0	0.5
	—	−3.6	5.2	9.2	−9.4
	—	−29.1	1.6	0.4	−25.0
	—	−0.2	0.5	0.8	−0.4
	—	2.2	−0.9	0.1	0.0
	—	−0.7	2.0	2.5	−7.5
	—	−0.2	0.0	0.0	0.0
	—	−3.1	3.7	−3.5	12.0
	—	2.3	−1.4	1.2	0.2
	—	0.2	0.0	0.0	0.0
	—	0.2	−0.1	−7.9	8.3
	—	0.0	−0.4	0.0	0.0
	—	−0.4	−0.3	0.3	0.9
	—	1.1	0.2	0.6	0.0
Cash from operating activities
	150	69.5	35.5	27.3	35.7
	—	8.8	40.5	32.5	−4.0
	—	78.3	76.0	59.8	31.7
	—	14.1	11.5	11.7	8.1
	—	64.1	64.5	48.1	23.6
Cash from investing activities
	—	17.8	20.6	24.4	77.8
	—	0.4	0.3	0.1	0.0
	—	7.5	0.0	0.0	0.0
	—	5.5	0.0	0.0	0.0
	—	2.0	0.8	1.9	0.5
	—	−0.9	0.5	−0.2	0.2
	—	−3.3	−19.0	−22.7	−77.0
Cash from financing activities
	—	0.0	0.0	20.5	56.1
	—	35.9	33.1	50.5	17.1
	—	0.3	0.3	0.3	0.0
	—	—	—	0.0	0.1
	—	6.6	13.1	14.9	12.6
	—	6.0	5.2	6.8	8.5
	—	0.0	0.0	26.0	24.0
	—	−48.8	−51.7	−26.0	41.8
	—	12.1	−6.2	−0.6	−11.6
	—	−14.9	−0.5	0.2	0.1
	—	−2.8	−6.7	−0.4	−11.6
	—	—	—	12.7	13.2
Reference items
	86.6	86.7	61.1	53.7	50.6
	26.6%	26.1%	19.6%	17.6%	19.0%
	46.3	46.3	43.9	23.7	−54.2
	—	20.2	−0.5	−20.3	—
	₹54.44	₹54.44	₹51.63	₹27.90	−₹63.67
	41.21×	—	—	—	—
	—	1.12×	2.24×	2.27×	0.84×
	—	14.1	11.5	11.7	8.1
	—	6.6	13.1	14.9	12.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HESTERBIO₹2,243.70

Hester Biosciences Limited

· Pharma & Health

₹ CrorePeersWINDLAS SYNCOMF NGLFINE INDOCO SAIPARENT JAGSNPHARM PANACEABIOMcap ₹1,909 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	9.4	17.2	16.8	18.9	—
+ Finance Costs	9.0	19.5	12.2	10.3	—
+ Interest Income	-2.2	-1.9	-2.0	-1.6	—
+ Fair Value (Gains) / Losses	0.0	0.0	0.0	-1.8	—
+ Unrealised FX (Gain) / Loss	0.1	-0.1	-0.8	10.9	—
+ Other Non-cash Items	0.0	-5.8	4.4	6.2	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	0.0	-2.9	—
+ Other Reconciling Items	0.5	0.0	0.0	0.0	—
Changes in Working Capital
+ Inventories	-9.4	9.2	5.2	-3.6	—
+ Trade Receivables — Current	-25.0	0.4	1.6	-29.1	—
+ Other Financial Assets — Current	-0.4	0.8	0.5	-0.2	—
+ Other Financial Assets — Non-current	0.0	0.1	-0.9	2.2	—
+ Other Current Assets	-7.5	2.5	2.0	-0.7	—
+ Other Non-current Assets	0.0	0.0	0.0	-0.2	—
+ Trade Payables — Current	12.0	-3.5	3.7	-3.1	—
+ Other Financial Liabilities — Current	0.2	1.2	-1.4	2.3	—
+ Other Financial Liabilities — Non-current	0.0	0.0	0.0	0.2	—
+ Other Current Liabilities	8.3	-7.9	-0.1	0.2	—
+ Other Non-current Liabilities	0.0	0.0	-0.4	0.0	—
+ Provisions — Current	0.9	0.3	-0.3	-0.4	—
+ Provisions — Non-current	0.0	0.6	0.2	1.1	—
Cash from Operating Activities
Profit Before Tax (per I/S)	35.7	27.3	35.5	69.5	150.0
+ Total Adjustments (incl. Working Capital)	-4.0	32.5	40.5	8.8	—
Cash from Operations (pre-tax)	31.7	59.8	76.0	78.3	—
+ Income Taxes Paid	8.1	11.7	11.5	14.1	—
Cash from Operating Activities	23.6	48.1	64.5	64.1	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	77.8	24.4	20.6	17.8	—
+ Disp of Fixed Assets	0.0	0.1	0.3	0.4	—
+ Disp of Subsidiaries / Businesses (net)	0.0	0.0	0.0	7.5	—
+ Loans & Advances Repaid	0.0	0.0	0.0	5.5	—
+ Interest Received — Investing	0.5	1.9	0.8	2.0	—
+ Other Inflows / (Outflows) — Investing	0.2	-0.2	0.5	-0.9	—
Cash from Investing Activities	-77.0	-22.7	-19.0	-3.3	—
Cash from Financing Activities
+ Proceeds from Borrowings	56.1	20.5	0.0	0.0	—
+ Repayment of Borrowings	17.1	50.5	33.1	35.9	—
+ Payment of Lease Liabilities	0.0	0.3	0.3	0.3	—
+ Payment of Finance Lease Liabilities	0.1	0.0	—	—	—
+ Interest Paid	12.6	14.9	13.1	6.6	—
+ Dividends Paid	8.5	6.8	5.2	6.0	—
+ Other Inflows / (Outflows) — Financing	24.0	26.0	0.0	0.0	—
Cash from Financing Activities	41.8	-26.0	-51.7	-48.8	—
Net Changes in Cash (pre-FX)	-11.6	-0.6	-6.2	12.1	—
+ Effect of FX Rate Changes on Cash	0.1	0.2	-0.5	-14.9	—
Net Changes in Cash	-11.6	-0.4	-6.7	-2.8	—
Closing Cash	13.2	12.7	—	—	—
Reference Items
EBITDA	50.6	53.7	61.1	86.7	86.6
EBITDA Margin %	19.02	17.62	19.62	26.05	26.59
Free Cash Flow (CFO − Capex)	-54.2	23.7	43.9	46.3	46.3
Free Cash Flow to Equity	—	-20.3	-0.5	20.2	—
Free Cash Flow per Basic Share	-63.67	27.90	51.63	54.44	54.44
Price to Free Cash Flow	—	—	—	—	41.21
Cash Flow to Net Income	0.84	2.27	2.24	1.12	—
Cash Paid for Taxes	8.1	11.7	11.5	14.1	—
Cash Paid for Interest	12.6	14.9	13.1	6.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.